Vanucizumab ELISA Kit (DT073038)

データシート製品共有情報コピー

概要
イメージ
参考文献
データシート
SDS

カタログ番号	DT073038
説明	Vanucizumab ELISA Kit (DT073038) — Quantitative sandwich ELISA for Vanucizumab. Sample: Plasma, Serum. Range: 0.31-5 μg/mL. Sensitivity: 0.156 μg/ml. Highlights ●Sandwich Format — High specificity, reliable quantification. ●High Sensitivity — Optimized for low-abundance target detection. ●Ready-to-Use — Complete kit with pre-coated plates included.
サンプルタイプ	Plasma, Serum
感度	0.156 μg/ml
レンジ	0.31-5 μg/mL
アクセッション番号	P15692 & O15123
アプリケーション	ELISA
検出方法	Colorimetric
アッセイタイプ	Quantitative
回収率	80-120%
発送	2-8 ℃
安定性と保存	The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
仕様	Vanucizumab
別名	RG-7221, RG7221, RO5520985, 1448221-05-3
背景	Vanucizumab (RG7221) is an experimental humanized monoclonal antibody (mAb) designed for the treatment of cancer. Vanucizumab is a bi-specific mAb composed of two different heavy chains and two different light chains. One arm of the antibody binds Angiopoietin-2 (Ang2) and the other is based on bevacizumab (Avastin), binding vascular endothelial growth factor A (VEGF-A). The antibody is designed to inhibit both VEGF-A and Ang2 simultaneously to offer superior clinical benefit compared to VEGF-A inhibition alone. This drug was developed by Genentech/Roche. On 12 Mar 2018, Roche completes a phase I trial in solid tumors (combination therapy, late-stage disease, metastatic disease, second-line therapy or greater) in Spain, France, and Belgium.
注意事項	For Research Use Only.